MARKET

TMBR

TMBR

Timber Pharmaceuticals
AMEX

Real-time Quotes | Nasdaq Last Sale

0.8903
-0.0197
-2.16%
After Hours: 0.8900 -0.0003 -0.03% 19:57 09/24 EDT
OPEN
0.9400
PREV CLOSE
0.9100
HIGH
0.9400
LOW
0.8800
VOLUME
575.54K
TURNOVER
--
52 WEEK HIGH
3.650
52 WEEK LOW
0.6651
MARKET CAP
32.64M
P/E (TTM)
23.62
1D
5D
1M
3M
1Y
5Y
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks?
Benzinga · 08/30 14:22
BRIEF-Timber Pharmaceuticals Announces Last Patient Last Visit In Phase 2B Control Study Evaluating Tmb-001 In Moderate To Severe Congenital Ichthyosis
reuters.com · 08/24 14:57
Timber Pharmaceuticals Discloses Last Patients' Completion of Phase 2b Study for TMB-001
MT Newswires · 08/24 13:20
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
- Topline results expected to be announced in the fourth quarter of 2021 -
GlobeNewswire · 08/24 12:00
BRIEF-Timber Pharmaceuticals - Qtrly Loss Per share $0.08
reuters.com · 08/10 13:57
Timber Pharmaceuticals Q2 EPS $(0.08) Up From $(1.36) YoY
Timber Pharmaceuticals (AMEX:TMBR) reported quarterly losses of $(0.08) per share. This is a 94.12 percent increase over losses of $(1.36) per share from the same period last year.
Benzinga · 08/10 12:25
-- Earnings Flash (TMBR) TIMBER PHARMACEUTICALS Reports Q2 Revenue $388,819
MT Newswires · 08/10 08:08
Insider Trends: Insider Prolongs 90-Day Selling Trend at Timber Pharmaceuticals
MT Newswires · 06/15 19:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TMBR. Analyze the recent business situations of Timber Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TMBR stock price target is 2.250 with a high estimate of 2.250 and a low estimate of 2.250.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 880.79K
% Owned: 2.40%
Shares Outstanding: 36.66M
TypeInstitutionsShares
Increased
5
172.81K
New
5
78.64K
Decreased
5
557.09K
Sold Out
7
10.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chief Executive Officer/Director
John Koconis
Chief Financial Officer/Executive Vice President
Joseph Lucchese
Chief Operating Officer/Executive Vice President/Secretary/Director
Zachary Rome
Chief Accounting Officer
Joyce Goto
Other
Alan Mendelsohn
Director
Gianluca Pirozzi
Director
Edward Sitar
Independent Director
David Cohen
Independent Director
Lubor Gaal
No Data
About TMBR
Timber Pharmaceuticals, Inc. (Timber) is a clinical-stage biopharmaceutical company. It is focused on development of treatments for orphan dermatologic diseases. It Is also focused on developing non-systemic treatments for dermatologic diseases, including congenital ichthyosis, facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. The Company's pipeline programs include TMB-001, TMB-002 and TMB-003. TMB-001 is topical formulation of isotretinoin, evaluated in a Phase II b clinical trial for the treatment of congenital ichthyosis (CI), a genetic keratinization. TMB-002 is a topical formulation of rapamycin, evaluated in a Phase II b clinical trial for the treatment of FAs in TSC, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. TMB-003 is a formulation of sitaxsentan in the preclinical development for the treatment of scleroderma, a rare connective tissue disorder characterized by abnormal thickening of the skin.

Webull offers kinds of Timber Pharmaceuticals Inc stock information, including AMEX:TMBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TMBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TMBR stock methods without spending real money on the virtual paper trading platform.